Nanoparticle based Photothermal Therapy for Breast Cancer
Alfa Cytology provides specialized preclinical CRO services for developing nanoparticle-based photothermal therapy (PTT) solutions targeting breast cancer. By leveraging nanotechnology and laser-induced hyperthermia, we help advance novel treatment strategies aimed at selectively eradicating tumor cells while minimizing systemic side effects.
Our Services
Nanoparticle Design & Synthesis
Customized design and synthesis of photothermal nanoparticles, including gold nanorods, hollow copper sulfide nanoparticles, carbon-based materials, and polymeric nanocarriers.
In Vitro Photothermal Efficacy Evaluation
Assessment of nanoparticle-mediated photothermal effects using breast cancer cell lines in 2D and 3D tumor spheroid models, including viability, apoptosis, and heat generation assays.
In Vivo Photothermal Therapy Studies
Evaluation of nanoparticle distribution, tumor accumulation, and photothermal tumor ablation in breast cancer mouse models, supported by real-time imaging and histological analysis.
Pharmacokinetics and Safety Profiling
Comprehensive preclinical testing of nanoparticle biodistribution, clearance, and toxicity to support further therapeutic development.
Key Advantages
| Customizable Nanoparticle Platforms | A broad range of nanoparticle types, sizes, surface modifications, and photothermal agents are available to meet specific breast cancer therapy requirements. |
| Advanced 2D and 3D In Vitro Models | Both monolayer and spheroid-based breast cancer models are used to simulate tumor microenvironments, improving the predictive value of photothermal efficacy data. |
| Reliable In Vivo Efficacy Studies | Preclinical models provide robust evaluation of tumor targeting, heat-induced tumor regression, and systemic safety—critical for translational research. |
| Preclinical Regulatory Support | All studies are conducted under preclinical quality standards, with complete data packages designed to support early-stage regulatory planning and product development. |
Download our service brochure to learn how our nanoparticle-based photothermal therapy solutions can enhance your breast cancer preclinical research. For tailored project consultation or service inquiries, please contact us today.
Case Study - In Vivo Efficacy Evaluation
The in vivo photothermal therapy (PTT) efficacy mediated by the mAbNectin-4-ICG conjugate was further evaluated in MDA-MB-468 tumor-bearing mice using 808-nm laser irradiation and monitored via [Assessment Method, e.g., Relative tumor growth curves and tumor weights].
Fig.1 Relative tumor growth curves in each group.
Fig.2 The tumor weights on the 30th day post
The relative tumor volume–time curves (Fig. 1) showed a negative growth trend in the mAbNectin-4-ICG + laser group, and the tumors on the 15th day were almost unmeasurable (volume recorded as 0 mm3), suggesting the tumors were completely ablated. At day 30, excised tumors in the mAbNectin-4-ICG + laser group weighed 0.00 ± 0.00 mg, significantly lower than other groups (Fig. 2). These results demonstrate that only tumor-targeting mAbNectin-4-ICG-mediated photothermal therapy (PTT), combining specific binding and photothermal conversion, achieves effective thermal ablation and sustained tumor inhibition.
